• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

New Report Contains In-Depth Analysis of Phase II and III Clinical Development Compounds for the Treatment of HIV

Posted on: Monday, 4 February 2008, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c81552) has announced the addition of Datamonitor's new report: Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need to their offering.

Treatment of HIV has come a long way since the discovery of the virus. Although no real cure has been found yet, the last few decades have seen the introduction of many classes of drugs that suppress the replication of the virus. As therapeutics have improved dramatically in terms of efficacy, safety and convenience, the bar for new drugs has been raised considerably.

Scope

- In-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugs

- Overview of the key companies involved in the HIV pipeline

- The epidemiology dynamics of HIV in the six major markets are discussed along with unmet needs that have evolved from the prolonged use of HAART

- Sales forecasts over the next 10 years for the each of the late-stage drugs

Highlights of this title

Class drug resistance represents a major problem for the NNRTIs. The two late stage compounds, developed by Tibotec/J&J, address this issue. etravirine is the more advanced of the two, but rilpivirine convenient dosing schedule makes it the commercially more promising candidate.

New NRTIs in development have not generated much excitement in the HIV community since most of these compounds, including Avexas apricitabine, Achillions elvucitabine and Pharmassets Racivir. have only made slow progress over the last few years.

Historically, emerging drug resistance may have signaled overall treatment failure and hastened the onset of AIDS. While newer classes of drugs will enable patients with complex drug resistance to continue with successful antiretroviral therapy, exactly how they will be incorporated into traditional HAART regimens remains unclear at this stage.

Key reasons to purchase this title

- Understand the constantly evolving market dynamics of antiretroviral drugs

- Understand the changing unmet needs of patients and the extent to which pipeline drugs are addressing these issues

- Evaluate the forecast of key pipeline antiretroviral drugs to 2016, taking into account key launch dates, adressing of unmet needs and other factors

Companies Mentioned:

Abbott Laboratories

Aftermarket Technology Corp.

Ambrilia Biopharma Inc

Barrier Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CDC SPA

Future plc

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Greaves Cotton Limited

Health Protection Agency

IMS Health

Insight Communications Company, Inc.

Japan Tobacco Inc.

Johnson & Johnson

Medivir

Merck & Co., Inc.

Miller Group Limited, The

Panacos Pharmaceuticals, Inc

Pfizer Inc

Progenics Pharmaceuticals, Inc.

Safety Insurance Group, Inc.

Schering-Plough Corporation

Tanox, Inc.

Trimeris, Inc.

Webster Financial Corporation

For more information visit http://www.researchandmarkets.com/reports/c81552

Source: Datamonitor

Source: Business Wire

More News in this Category